Premium
P2‐213: Association of CSF biomarkers to regional rates of FDG‐PET metabolism in the Alzheimer's disease continuum
Author(s) -
Tosun Duygu,
Weiner Michael
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.920
Subject(s) - biomarker , medicine , dementia , imaging biomarker , neuroimaging , oncology , alzheimer's disease neuroimaging initiative , pathology , positron emission tomography , disease , stage (stratigraphy) , nuclear medicine , neuroscience , magnetic resonance imaging , psychology , biology , radiology , biochemistry , paleontology
PS1 subjects (P<0.001). Hippocampal atrophy was greater at symptom onset in APP (2.17% (1.68, 2.65)) compared to PS1 (1.13% (0.70, 1.56)), with evidence of acceleration in rates in both groups. Rates of ventricular enlargement were similar in APP (13.5% (9.1, 18.1)) and PS1 (11.6% (7.9, 15.4)), but there was evidence of greater acceleration in PS1 (P 1⁄4 0.006). Conclusions: Increased atrophy rates, relative to controls, are clearly evident in mutation carriers at time of symptom onset. Hippocampal atrophy rates appear higher in APP subjects compared to PS1, but global (whole brain and ventricles) rates are similar. Atrophy rates show evidence of acceleration, with greater acceleration in PS1 subjects for global measures.